Erschienen in:
01.07.2007 | Letter
Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267
verfasst von:
M. A. Nauck, M. Trautman, R. Brodows, D. Johns, J. Northrup, D. Kim
Erschienen in:
Diabetologia
|
Ausgabe 7/2007
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: In his letter to
Diabetologia [
1], P. D. Home highlights the difficulties of achieving optimal glycaemic control with insulins. While good glycaemic control was achieved with insulin (endpoint HbA
1c about 7.0% on average) in the several recently published trials identified by Home [
1], other trials have reported less than optimal results, particularly for insulin mixtures [
2,
3]. Subjects in the treat-to-target trial conducted by Janka et al. [
3] achieved a mean endpoint HbA
1c of 7.49% with human NPH insulin 70/30. Subjects treated with biphasic insulin aspart 30 in the study conducted by Boehm et al. [
2] achieved a mean HbA
1c of 8.15% at endpoint. Incidentally, this study [
2] was used as a reference when designing our non-inferiority study [
4]. …